Wall Street talking about Indian pharma companies? BD
Drug giant Pfizer said this afternoon that it would raise its quarterly dividend by 3 cents a share to 32 cents, for shareholders of record on Feb. 8. The increase comes in spite of, or maybe because of, all the pressure the drug giant is feeling from generics.
So if you can’t beat them, maybe you’d like to own them? Investors may want to add Indian generic drug makers to their portfolios, the WSJ’s Heard on the Street said today.
Share of many Indian generic companies on the Bombay Stock Exchange have been bruised by Big Pharma’s recent success in defending some brand-name patents, international competition and a stronger rupee. The stock prices have fallen so much that some think companies such as Dr. Reddy’s Laboratories Ltd. and Cipla Ltd. could now be appealing buys.
Health Blog : Time to Invest in Indian Generics?
Hat Tip: Kevin, MD
0 comments :
Post a Comment